Full Press Release Details
Eidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy At The AHA 2018 Scientific Sessions In A Late-breaking Featured Science Oral Presentation.
BBIO
Eidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy At The AHA 2018 Scientific Sessions In A Late-breaking Featured Science Oral Presentation
Key Takeaway: Eidos Therapeutics To Present Phase 2 Data For AG10 In TTR Amyloidosis Cardiomyopathy At The AHA 2018 Scientific Sessions In A Late-breaking Featured Science Oral Presentation
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis